The phenomenon of liquefaction of human fibrin clots by broth cultures or culture filtrates of beta hemolytic streptococci was first described by Tillett and Garner in 1933 (1) . The complex mechanism of this reaction, thought at first to be a direct fibrinolytic effect of a streptococcal enzyme, has been elucidated in recent years. Milstone (2) demonstrated that a substance present in plasma, termed "lytic factor," is required for dissolution of the clot; and as a result of the work of Christensen (3, 4) , confirmed independently by Kaplan (5) , it is now known that the "lytic factor" is a proteolytic enzyme normally present in the plasma as an inactive precursor. The role of the active streptococcal substance is that of an activator of the proteinase precursor, converting it into an active enzyme in a manner analogous to the conversion of trypsinogen to trypsin by enterokinase. The active serum proteinase is responsible for digestion of the fibrin clot. In view of the accumulated evidence regarding the nature of streptococcal fibrinolysis, Christensen and MacLeod (6) have proposed the term streptokinase to replace the term fibrinolysin originally applied to the streptococcal component of the system. They have further suggested the name plasminogen for the inactive form of the serum proteinase and plasmin for the active enzyme. This terminology has been adopted in the present report.
The activity of streptokinase derived from group A hemolytic streptococci in promoting the lysis of human fibrin clots is in sharp contrast to its minimal effect on clots of other animal species (1, 4, 7, 8) . Although the basis for the apparent human specificity remains somewhat uncertain, this property of streptokinase is unique and other products of streptococcal cells, such as streptolysin, erythrotoxin, and streptococcal proteinase do not exhibit comparable specificity. Thus, streptokinase deserves special attention in the study of rheumatic fever, which is a sequela of streptococcal infection that appears to be limited to the human species.
Numerous immunological studies on streptokinase (fibrinolysin) have been carried out with human plasma (9, 10, 11, 12, 13) using the antifibrinolysin test described by Tillett and Garner (1) , but because of the essentially qualitative nature of the test, it has not been possible to obtain definitive information comparable to that derived from the more precise quantitative titrations of other serum antibodies. Kaplan (15) . The next morning sterile 50 per cent glucose solution (40 cc. per liter of culture) and phenol red (10 mg. per liter of culture) were added to the culture and incubation continued another five hours during which time the pH of the culture was maintained at or slightly above 7.0 by the frequent addition of 5N NaOH. This procedure resulted in a tenfold increase of streptokinase activity. The culture was centrifuged and the supernate filtered through a Coors No. 3 filter. Approximately 300 cc. of nondialyzed neopeptone broth had previously been passed through this filter, because it was found that a filter not so treated quantitatively absorbs streptokinase out of 2 We are indebted to Sharp and Dohme, Inc., for a generous supply of Fraction I. 3 Manufactured by Parke, Davis and Co. 4 Strain H105 was obtained from Dr. W. S. Tillett and was designated Co in his laboratory (1) . dialyzed neopeptone broth.. One-cc. amounts of the sterile filtrate were placed in small tubes and stored in a CO2 chest at -700 C.
Standardization of streptokinase: The procedures used for the standardization of streptokinase and for the quantitative determination of antistreptokinase are similar to, but not identical with, those described by Kaplan (14) . In each of a series of tubes were placed the following: 1.0 cc. of varying dilutions of streptokinase, 1.0 cc. of 0.6 per cent Fraction I solution, and 0.2 cc. of the thrombin solution. The tubes were immediately shaken and, when clotting had occurred, were incubated in a water bath at 370 C. for 30 minutes. The highest dilution of streptokinase which just effected complete dissolution of the fibrin clot was used in the determination of antistreptokinase.
Determination of antistreptokinase in serum: Twofold dilutions of serum were used, beginning with a dilution of 1: 10. To 0.5 cc. of the serum dilutions was added 0.5 cc. of streptokinase in the dilution determined by the method outlined above. These tubes were mixed by shaking and then incubated in a water bath at 37°C. for 30 minutes to allow for antigen-antibody combination. According to Kaplan (16) this is 95-98 per cent complete in 30 minutes. The tubes were then placed in an icewater bath to prevent as far as-possible any enzymatic activity during the time required for the addition of the indicator system. To each tube was added 1.0 cc. of the 0.6 per cent Fraction I solution (containing plasminogen and fibrinogen). There was then added 0.2 cc. of the thrombin solution and the tubes shaken immediately to insure the formation of a uniform clot. The tubes were re-incubated at 37°C. for 60 minutes. The criteria for reading the rest are those described by Kaplan. The endpoint was taken as the reciprocal of the serum dilution which completely prevented lysis of the clot as determined by the failure of the clot to slide when the tube was gently tapped in the inverted position. As a control on the activity of the streptokinase preparation, a tube in which the serum dilution was replaced by buffered saline solution was included in each series of dilutions. Complete lysis was expected in this tube. The largest number of sera which could be conveniently tested at one time was found to be six. An indication of the reproducibility of the test is given by the results of 50 repeat titrations. The end-points were identical in 38, and varied by only one tube in the remaining 12. Therefore, a rise in antibody titer of two or more tubes was considered to be significant.
Antistreptolysin 0: The method used for the determination of antistreptolysin 0 was that described by Todd as modified by Hodge and Swift (17) . A two-tube rise in titer was considered significant. It should be noted that the dilution increments in the determination of antistreptolysin 0 differ from those used in the antistreptokinase test.
Gamma globulin: The gamma globulin levels were determined by the turbidimetric method described by Kunkel (18 In Figures 1-3 , the arithmetic means of the three determinations are plotted against the week of disease. It will be seen at once from an inspection of these figures that, in general, the pattern of response within each group is similar in all three determinations. For example, the group of rheumatic fever patients (Group V) has consistently higher antibody titers and gamma globulin levels throughout the period studied than any of the other groups. The possible significance of this finding will be considered in detail below. In addition, there is a consistent difference between the degree of response of those untreated scarlet fever patients with single type infections (Group I) and those with multiple type or cross infections (Group II). The Groups as in Figure 1 .
The failure of production of antibodies to streptokinase and streptolysin 0 in those patients "successfully" treated with penicillin (Group III) is apparent from inspection of Tables I and II, and (21) , and by Weinstein and Tsao (22) . In contrast to the flattened curves seen in Figures 1 and 2 for this group (Group III), the average gamma globulin levels ( Figure 3) show a rise comparable to those of Groups I and IV. This suggests that the antibody response as a whole may not be greatly suppressed by the administration of penicillin. The two specific antibodies measured are directed against extracellular products elaborated by growing streptococcal cells, and may represent special cases with respect to the effect of penicillin on antibody production. I  17  65  76  53  88  II  12  75  58  42  92   III  17  0  47  P0  47  IV  21  71  76  62   90  V  23  87  83  74  96 The proportion of patients in each group showing significant rises in antistreptokinase and antistreptolysin 0 titers may be seen in Table II . With the exception of Group III, the incidence of significant responses of the two antibodies is similar within each group. The percentage difference in Group III is probably more apparent than real for the reason mentioned before. As demonstrated by the data given in the last two columns of Table II method the normal range has been found to be about 0.67-1.0 gm. per cent (18) .
The occurrence of consistently higher mean values for the two antibodies as well as for the gamma globulin levels in that group of patients with rheumatic fever (Group V) as compared with the other groups is worthy of special reference. Although the number of uncontrollable variables inherent in a study of this kind may cast some doubt on the validity of applying statistical methods, the results of statistical analysis of these data suggest that the observed differences are significant. For example, in the case of the mean value for the serum gamma globulin at three weeks after the onset of scarlet fever, the observed difference between the rheumatic fever patients and the entire non-rheumatic group is four times its standard error. According to statistical theory, the probability of this difference occurring by chance is 1 in 15,000.
There are additional considerations which appear to support the interpretation that the observed difference is significant. To provide graphic representation of the observations, the mean weekly value of each of the three determinations for the 67 scarlet fever patients in Groups I-IV have been subtracted from the corresponding mean values for the rheumatic fever patients (Group V) and the differences plotted in Figure  4 . Figure 5 . At the time of the initial bleedings, the frequency distribution of the titers is remarkably similar for the two groups. By the end of 21 days, however, the two distributions have lost their similarity, and the one for the rheumatic fever group has shifted more to the right than has the one for the nonrheumatic fever group. Similar analyses of the antistreptolysin 0 and gamma globulin data yield comparable results. Thus this treatment of the data appears to support the significance of the differences between the rheumatic and non-rheumatic groups that was first suggested by the mean values of the various determinations.
In vitro production of streptokinase: Because previously published work (19) suggested that the antistreptokinase response of the patient was somewhat proportional to the quantity of streptokinase produced in vitro by the infecting organism, a number of group A hemolytic streptococci isolated from patients in this investigation were studied for their ability to produce streptokinase. Ninety-four assays were performed, using 62 different strains. Supernates of ten Type 1 and ten Type 3 streptococcal cultures were tested, and, without exception, all failed to lyse a standard clot even when tested undiluted. These two types were far less common during the epidemic than were the other types, so that untreated patients from whom only a Type 1 or a Type 3 streptococcus was isolated were few in number, and only two are represented in Table I . Neither has a significant antistreptokinase response. Forty-two group A hemolytic streptococci of Types 17, 19, and 30 were tested, and all produced measurable amounts of streptokinase. The supernates of two strains could be titered only to a dilution of 1: 5; all the rest titered to dilutions of 1: 10 or 1: 20. There was no difference in ability to produce streptokinase between those organisms isolated from patients with rheumatic fever, and those from patients who did not develop rheumatic fever.
DISCUSSION
The results of the present studies provide no evidence that those patients who develop rheumatic fever following group A hemolytic streptococcal infections have a pattern of antibody response to streptokinase that differs from the pattern of their response to other antigenic stimuli. On the contrary, the quantitative differences in antistreptokinase production which are observed in a comparison of the rheumatic and non-rheumatic patients are paralleled by comparable differences in the production of a second antibody, antistreptolysin 0, and in the increase in serum gamma globulin. The data on gamma globulin suggest that the greater production of the two antibodies in those patients who developed rheumatic fever is a reflection of a general augmentation of antibody formation.
It is important to point out that in the present study the increased antibody production is made apparent only by the collective analysis of the two groups of cases, and no basis is provided for differentiating between individual patients. Thus, some of the patients with uncomplicated scarlet fever showed a greater rise in antibody titer than certain of the rheumatic fever patients, and a few of the latter have relatively insignificant increases.
Quantitative differences in production of antibody have not been emphasized in previous investigations of group A hemolytic streptococcal infections in which rheumatic and non-rheumatic patients have been compared (23, 24, 25, 26, 27) . In a recent study, Rothbard, Watson, Swift, and Wilson (28) found that the average antistreptolysin 0 response, as indicated by the ratio between the maximal titer and initial titer, was greater in patients who developed rheumatic fever following a streptococcal infection than in those who had uncomplicated infections. However, they found in addition that a group of patients with purulent complications showed a much greater average response than either of the other two groups. The fact that the differences described in the present study are so readily apparent may be in some degree due to the homogeneity of the case material. These patients were selected from a single epidemic of scarlet fever occurring within a period of two months, and a relatively small number of streptococcal strains was involved. Furthermore, the patients represented an unusually uniform sample of the population, since all were males between the ages of 17 and 27; 82 (91 per cent) of the men were included in the age group of 17 to 20 years. Accordingly, some of the uncontrollable variables commonly present in this type of study were eliminated, and it is reasonable to suppose that small differences of the sort described might become apparent under these conditions.
The possible significance of the apparent enhancement of antibody formation in the rheumatic subjects is difficult to assess. Conceivably it might mean that on the average these patients received a greater antigenic stimulus in the form of a more serious or extensive streptococcal infection, although there is nothing in the clinical histories to support this point of view. A second possible interpretation is that persons susceptible to rheumatic fever may in general respond to a given stimulus with greater production of antibody. It is well known, for example, that individual differences in degree of antibody formation occur among experimental animals injected with identical amounts of antigen. It is also worthy of note that even at the onset of the streptococcal infection, those patients who later developed rheumatic fever had, on the average, higher antibody titers and higher gamma globulin levels than did those who did not develop rheumatic fever. Regardless of the interpretation one wishes to put on the results, it seems premature and fruitless to attempt to reconcile them with any of the current theories concerning the pathogenesis of rheumatic fever. SUMMARY AND CONCLUSIONS 1. A procedure for the quantitative determination of antistreptokinase has been employed to follow the antibody response of patients with scarlet fever, including those who developed rheumatic fever. Antistreptolysin 0 titers and gamma globulin levels on the same sera are presented for comparison.
2. There is suggestive evidence that the presence of two or more types of streptococci during an infection calls forth a greater antibody response than does the presence of only a single type.
3. Early and effective 'penicillin therapy which removed the infecting organism promptly from the nasopharynx either prevented entirely or greatly decreased the expected antibody response to streptokinase and streptolysin 0. No effect was apparent on the total antibody response as measured by the serum gamma globulin. 5. Of the patients included in this study, it would seem that on the average those who developed rheumatic fever as a sequela to a streptococcal infection exhibited a greater antibody response than those who did not develop rheumatic fever.
